Outlier Ambition.Transformational Tech.Compounding Execution.

Venture capital produces two returns: financial and strategic. Traditional funds are built to optimise the first, and they do it well. They pool capital from many backers, so one mandate has to suit them all.

Artesian also invests for financial return, but many of our funds are built around a specific institution and what it wants to achieve.

For builders, that can mean more than capital. Our backers are strategic institutions: governments, corporations, industry bodies, superannuation funds and universities. They bring sector knowledge, networks, infrastructure, procurement pathways and potential customers. This can give a company access to an ecosystem that helps it test, commercialise and scale its technology.

The investment standard does not change. We back companies capable of becoming valuable, independent businesses, not projects designed to serve one backer.

Traditional VC brings capital and investment expertise. Artesian combines both with a mandate and ecosystem built around the market a builder is trying to change.

Not necessarily. Sometimes it means exactly that. Sometimes it means “not right for that fund”, and those are different problems.

VC has become more flexible. Funds can sell shares through secondary transactions, and an acquisition can return capital well before an IPO. But neither route removes the pressure of a fixed fund life. A secondary buyer may not appear when needed, and a strategic acquisition cannot be assumed. Many funds still favour companies that can scale quickly with relatively little capital.

That can work against hardware, deep tech and regulated businesses with long development cycles, even when the opportunity is real.

Artesian builds funds with institutions that understand these markets and can take a longer view. They may also bring customers, infrastructure, procurement pathways and industry relationships that help a company commercialise and make a strategic exit more credible.

Patient capital does not mean a lower standard. We still need a strong team, a large market, defensible technology, evidence of execution and an outcome that justifies the time and capital required.

We do not lower the bar. We judge the opportunity against what it actually needs.

Artesian invests across six broad themes. Each mandate is more specific, shaped by the backer's objectives, capabilities, geography and risk appetite.

• Agrifood: technologies that improve productivity, resilience and resource efficiency across food and agriculture, where industry bodies and agribusinesses have a direct interest in adoption.
• Energy transition: energy generation, storage, grids and industrial decarbonisation, driven by emissions targets, transition risk and surging demand from data centres and AI that existing energy systems were not built to carry.
• Health: technologies that improve prevention, diagnosis, treatment and care delivery as health systems face rising costs, ageing populations and workforce constraints.
• Defence: sovereign technologies that strengthen resilience, intelligence and operational capability while reducing reliance on external supply chains.
• AI and autonomy: technologies that increase productivity, address labour constraints and extend what corporations can research, produce and operate.
• Frontier: breakthrough science emerging from universities, research institutes and technical builders, often before an established market category exists.

The common thread is not sector alone. It is alignment between companies solving consequential problems and institutions that understand those problems, can support commercialisation and benefit as the market develops. That creates strategic demand around the capital without weakening financial discipline.

Yes: the filter is whether the technology is transformative and critical to the problem our backer needs solved, not its category. Sometimes that is software. Often it is hardware, biology or the physical systems software runs on.

We can hold the slow, capital-intensive kind, and we can go earlier than a generalist fund is comfortable going. A pooled fund with a ten year life has to close whatever stage the science is at, and without deep domain expertise it tends to underwrite technical risk by proxy, through traction, team pedigree and comparable raises. Our backers are often the actual domain experts: the government's own technical advisers, the industry body's own engineers, the research institute's own reviewers. That lets us properly diligence science a generalist fund would either pass on or misprice.

Capital is staged around technical and commercial milestones, from prototype to pilot to first commercial deployment, rather than sized to a growth curve that does not apply. Where non-dilutive capital exists, whether grants, government contracts or procurement programmes, we structure around it rather than equity-funding the whole development path, because the cheque shape should match what retiring the risk actually costs.

A government building sovereign capability needs satellites, materials and manufacturing. An industry body renewing its sector needs machinery, sensors and biology. A research institute needs its lab science commercialised.

Physical technology gains more from an industry-aligned backer than pure software does. A sensor, a device or a biological product needs a trial site, a regulatory pathway and a first buyer, and that is exactly what an industry-aligned backer can open.

There is no single Artesian entry stage. Each fund is designed for a particular risk profile, so our first investment in a company may be at pre-seed, seed, Series A or later. Across more than 600 portfolio companies, many were first backed early, but we also initiate positions in later rounds where the mandate calls for greater technical or commercial maturity.

Round labels are weak proxies, particularly in deep tech. A pre-revenue Series A may have retired substantial scientific, regulatory or manufacturing risk, while a revenue-generating seed company may still face significant product and market risk. We assess what has been proven, what remains uncertain and what the next capital will achieve.

Revenue is therefore evidence, not a gate. In life sciences, we may invest before a drug has been cleared to begin human trials. In hardware, we may invest before a customer has committed to using the technology in their own product. In other deep tech, we may invest before a real-world pilot has run. What matters in each case is whether the technical proof, the team and the financing plan are credible.

At any stage, we need a defensible technology, a defined value inflection and a credible path to a market large enough to support venture returns.

We invest through mandates, not around office locations. Each fund has an agreed geographic scope shaped by what its backer is trying to achieve.

For builders, the important distinction is between company location and outcome location. Some mandates require a company to be incorporated, headquartered or substantially operating within a defined market. A state-backed fund, for example, may be designed specifically to build local companies. Other mandates care less about where a company begins than where the strategic benefit is created: they may invest in a business headquartered elsewhere if it establishes manufacturing, employment, research, supply-chain capability or a meaningful commercial presence in the backer's region.

Separately, the funds themselves vary in reach. Some Artesian mandates are global by design and draw on our nine offices across the Americas, Europe and Asia Pacific; others remain deliberately narrow because developing a particular region or sovereign capability is part of their purpose. Much of our capital remains concentrated in Australia and New Zealand, where Artesian began, but our mandate base is becoming increasingly global.

Builders should ask about geographic eligibility early. The relevant question is not simply where your company is based, but what presence, capability or economic value the mandate requires you to build.

The best pitch explains why your company belongs with Artesian, not merely why it is venture-backable. Read our answers on sector, stage, revenue and geography first. They show which mandate you may fit and what it was built to achieve.

Lead with the standalone investment case: the problem, your solution, its defensibility, the market, your evidence and what the next capital will prove. Then identify the relevant Artesian sector and explain why that mandate is the right one.

Show what the institution behind the capital understands, needs or can unlock for your company. This might be technical expertise, infrastructure, regulation, procurement, industry access or a first commercial environment. Be specific. “Government is a customer” is not a strategy.

Strategic relevance strengthens an investment case; it does not replace one. We still need an independent company capable of venture-scale returns.

A warm introduction carries useful judgement, but it is not required. Cold submissions go directly to the venture team and are assessed on the same basis. Make either route recognisably for Artesian.

Every submission is read, but we cannot reply individually to each one. If there is a credible mandate fit, you will hear from us. The first conversation needs no elaborate deck and should be led by the people building the company.

Recognising quality and allocating capital are different problems. There is no single ranked queue competing for one pool of money. The venture team maps your company against our live mandates: sector, geography, stage, cheque size and risk profile. An exceptional company still needs a mandate able to invest in it.

For the submissions we follow up on, the first step is a 30-minute conversation. From that point we close the loop with one of three outcomes: no, with the principal reason; not yet, with the milestone or evidence that would change the answer; or progression to diligence.

Diligence is led by a named investment professional who remains accountable throughout. Its depth reflects the company's stage and risks, but may cover the market, technology, team, commercial model, financials, legal matters, ESG and mandate fit. Specialists are involved where required.

The deal lead then prepares a written recommendation for the relevant Investment Committee, which makes the investment decision.

Four things: the problem and who feels it acutely enough to act; why now, including what has changed in technology, regulation or market structure; why your team has a distinctive right to win; and what the next twelve months of capital will prove.

We are not looking for a polished retelling of the deck. We want to understand how you think about the business: which claims are supported by evidence, which are reasoned judgements and which remain assumptions. Knowing what you have not yet proved, and how you intend to prove it, is more useful than filling every gap with certainty.

We will also test whether the round is built around a genuine value inflection. “More growth” is rarely enough. We want to know what becomes technically, commercially or financially possible if the plan succeeds, and how that changes the company's risk.

The first conversation is usually thirty minutes with one or two members of the venture team. It is not full diligence, so you do not need to defend every technical assumption. Specialists join later where the opportunity and mandate fit justify deeper work.

The relevant fund's Investment Committee makes the decision, not the individual who sourced the opportunity or led the diligence.

Artesian runs the process end to end: assessment, diligence, the investment paper and the recommendation. Each mandate has its own Investment Committee and governance framework.

Where a fund has a single institutional backer, that institution participates directly in the Committee and is usually engaged during diligence. Its authority varies by mandate, from Committee participation to reserved approval rights over specified decisions. Those rights are agreed when the fund is established, not negotiated transaction by transaction.

The investment case remains Artesian's responsibility. Our deal team must establish the financial case, test the risks and recommend the investment before it reaches the Committee. Institutional involvement complements that work with strategic and domain judgement; it does not replace it.

Before diligence begins, we will tell you which mandate is considering your company and the institution behind it. Its involvement does not guarantee procurement, partnership or acquisition, but it means a strategically relevant institution is engaged from the outset.

We may back companies in adjacent markets, but within a single mandate we do not knowingly invest in direct competitors.

The distinction matters. Two companies may operate in soil analytics, for example, while serving different customers, geographies or use cases. Shared sector language does not necessarily mean commercial competition. We assess overlap based on where revenue is actually expected to come from, not the category attached to the company.

If the mandate considering you already holds a direct competitor, we will disclose that before any substantive discussion and will not seek confidential information before establishing whether we can proceed.

Across separate mandates, genuine overlap can occasionally arise. When it does, we use separate deal leads, information barriers, recusals and independent board representation. Confidential information remains with the team responsible for your company; it does not circulate through Artesian because another portfolio company operates nearby.

Conflict assessment also continues after investment. Companies pivot, markets converge and relationships that were complementary can become competitive. We review potential conflicts when considering follow-ons, board matters and new investments. If a material conflict emerges, we disclose it and manage it under our documented conflicts and allocation policy. You should hear it from us, not through a competitor's announcement.

Not for a pitch submission, first conversation or initial assessment. At that stage, you should assume the discussion is non-confidential and avoid sharing trade secrets or other information that cannot yet be disclosed safely.

We assess many companies in adjacent markets. An NDA signed before we understand the company or its mandate fit can create uncertainty around information we already know, receive independently or may later encounter through another opportunity. It can also restrict legitimate market assessment. That is why institutional investors rarely sign one before deciding to enter diligence.

This matters most at the earliest stage, where a company's real asset is usually the team and the pace of execution, not yet a protectable idea, and where the cost of managing NDAs with every fund you talk to is highest relative to what they would actually protect.

We still handle initial materials carefully. Access is limited to the relevant team and governed by our internal information controls. But we prefer to be precise: without an NDA, that treatment is not a contractual confidentiality obligation.

Once we begin formal diligence, we can enter an appropriate confidentiality agreement covering the technical, financial, customer and commercial information required. We will also make clear which mandate is considering the investment, who may receive the information and how an institutional backer participates in the process.

If your core value depends on a trade secret, unpublished patent claim or similarly sensitive information, tell us without revealing it. We can assess the opportunity at a higher level first, then structure detailed disclosure once suitable protections are in place.

Often. When we say lead, we mean taking responsibility for the round: negotiating the term sheet, directing diligence and committing an anchor cheque around which a syndicate can form. It does not simply mean writing the largest cheque into terms set by someone else.

We are willing to be the first committed investor and to help build the syndicate. We look for co-investors who add domain knowledge, commercial reach, follow-on capacity or another capability the company will need, not simply capital to complete the round.

The limit is consecutive insider-led pricing. If we lead an early priced round, we would not ordinarily set the valuation for the company's next priced round ourselves. That round should be tested and negotiated by an independent new investor. We may participate, but an external lead provides a more credible market price and avoids insiders validating their own mark.

A bridge or extension is different. Its purpose is usually to provide runway to a defined milestone, not establish a new independent valuation, so we assess and structure it accordingly.

If you want Artesian to lead, approach us early. We are most useful while the round, terms and syndicate are still being formed.

Yes, but follow-on capital is earned rather than automatic.

Follow-on capacity is designed into our funds from the outset. Depending on the mandate, we typically reserve 50 to 60% of committed capital for later rounds. The portfolio starts relatively broad while risk is difficult to distinguish, then becomes more concentrated as companies produce stronger technical, commercial and financial evidence. Each follow-on remains a new investment decision. Reserves are not allocated to companies in advance or deployed simply to maintain ownership.

The fund itself is only one source of later capital. Our co-investment relationships can bring institutional and strategic investors directly into larger rounds, particularly where capital requirements exceed the sensible capacity of an early-stage fund. Artesian may also establish later-stage vehicles that make separate, concentrated investments in the strongest companies across the platform. Neither source is guaranteed, but both extend the capital network beyond the original mandate.

A single fund will still limit its exposure to any one company, generally to 10 to 15% of the fund depending on its mandate and portfolio construction. Beyond that point, our role shifts from supplying most of the capital to helping the company attract the right external investors.

The practical answer is yes, but each round must be justified by the evidence available then.

We consider how value could ultimately be realised from the beginning, without pretending to predict the buyer or building the company for a single transaction.

There are three main routes. A trade sale is the most common, usually to a strategic acquirer that values the company's technology, market position or capability. A secondary sale can give builders and early investors partial liquidity, or bring in later-stage capital without selling the business. A listing suits fewer companies and requires sufficient scale, governance, predictability and public-market demand.

The likely route depends on sector and geography. A medical device company, agrifood platform and defence business will have different buyers, regulatory constraints and capital markets. Most venture funds see one market almost exclusively, usually the United States, which means their companies end up sold to American buyers by default rather than by choice. Our reach is wider by construction: New York and Austin connect to US late-stage capital and acquirers, London covers the UK and Europe, and Singapore and Shanghai cover Asia. That lets the exit path follow the company rather than the fund's home market.

An institutional backer may contribute sector knowledge, buyer relationships and strategic context. It may also become a potential acquirer. That does not give it a privileged exit or automatic right to buy. Any related-party proposal is managed through recusals, and priced by an independent valuation, a credible market test or both.

Ultimately, the company's board and shareholders assess any transaction under their own duties and rights. Strategic fit cannot substitute for fair value and a proper process.

Two potential advantages: access to institutions that shape your market, and capital whose priorities are not determined solely by the venture cycle.

Many Artesian funds are anchored by governments, corporations, universities or industry bodies already operating in the sector. They may bring technical expertise, infrastructure, trial environments, regulatory context, procurement pathways and relationships with customers or strategic partners. Several have piloted with, procured from or acquired portfolio companies.

That does not make the backer a guaranteed customer. Builders must still meet commercial, technical and procurement standards. The advantage is a shorter path to the people, operating environments and evidence needed to prove the product in the real market.

The capital base is also different. Government programmes, corporate balance sheets and industry levies are driven by different budgets, priorities and time horizons. They are not immune to economic pressure, leadership changes or shifting strategy, but they do not necessarily contract at the same time or for the same reasons as conventional venture fundraising.

That can make the platform more resilient when venture markets tighten. It does not make follow-on funding automatic. Each round must still earn support through evidence, and every mandate retains its own limits, governance and investment period.